- Home
- NGNE vs GFR Comparison
NGNE vs GFR Comparison
Compare NGNE & GFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NGNE
- GFR
- Stock Information
- Founded
- NGNE 2003
- GFR 2018
- Country
- NGNE United States
- GFR Canada
- Employees
- NGNE N/A
- GFR N/A
- Industry
- NGNE Biotechnology: Pharmaceutical Preparations
- GFR
- Sector
- NGNE Health Care
- GFR
- Exchange
- NGNE Nasdaq
- GFR Nasdaq
- Market Cap
- NGNE 325.3M
- GFR 321.0M
- IPO Year
- NGNE N/A
- GFR N/A
- Fundamental
- Price
- NGNE $20.51
- GFR $4.56
- Analyst Decision
- NGNE Strong Buy
- GFR
- Analyst Count
- NGNE 7
- GFR 0
- Target Price
- NGNE $41.86
- GFR N/A
- AVG Volume (30 Days)
- NGNE 123.0K
- GFR 21.4K
- Earning Date
- NGNE 08-11-2025
- GFR 08-06-2025
- Dividend Yield
- NGNE N/A
- GFR N/A
- EPS Growth
- NGNE N/A
- GFR N/A
- EPS
- NGNE N/A
- GFR 2.05
- Revenue
- NGNE N/A
- GFR $516,308,125.00
- Revenue This Year
- NGNE N/A
- GFR $3.00
- Revenue Next Year
- NGNE N/A
- GFR N/A
- P/E Ratio
- NGNE N/A
- GFR $2.22
- Revenue Growth
- NGNE N/A
- GFR N/A
- 52 Week Low
- NGNE $6.88
- GFR $3.81
- 52 Week High
- NGNE $74.49
- GFR $8.16
- Technical
- Relative Strength Index (RSI)
- NGNE 47.72
- GFR 53.41
- Support Level
- NGNE $18.94
- GFR $4.27
- Resistance Level
- NGNE $21.59
- GFR $4.69
- Average True Range (ATR)
- NGNE 1.40
- GFR 0.19
- MACD
- NGNE -0.26
- GFR 0.00
- Stochastic Oscillator
- NGNE 32.30
- GFR 63.04
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
About GFR Greenfire Resources Ltd.
Greenfire Resources Ltd explores, acquires, develops and produces oil and gas in the Canadian energy sector and internationally. Greenfire currently has two producing oil sand assets, Hangingstone Expansion and Hangingstone Demo. The Company has one reportable operating segment which is made up of its oil sands operations based on geographic location : Athabasca oil sands region of Alberta, Canada, nature of the products sold and integration of facilities and operations.